What BioMarin Pharmaceutical Inc.'s executives and directors are doing with their own shares, from SEC Form 3/4/5 filings — separating what the filings state (awards, withholding, disclosed plans) from what only the pattern of dates shows.
| 3 months | 12 months | |
|---|---|---|
| Open-market buys | 0 | 0 |
| Sells | 1 | 5 |
| Total trades | 3 | 49 |
| 3 months | 12 months | |
|---|---|---|
| Acquired | 6,140 | 291,928 |
| Disposed | 21,643 | 134,566 |
| Net activity | −15,503 | +157,362 |
View rich charts and dive into the patterns of specific insiders — who is accumulating, who is winding down, and which sale explanations the filings actually support.
| Insider | Relation | Date | Transaction | Shares | Price | Value | Shares held |
|---|---|---|---|---|---|---|---|
| Friberg Gregory R | EVP, Chief R&D Officer | Sep 30 | Withheld — tax / exercise cost · F | −4,086 | $60.00 | −$245K | 47,732 |
| Plenge Robert M | Director | Sep 10 | Grant / award · A | +6,140 | — | — | 6,140 |
| Davis George Eric | EVP, Chief Legal Officer | Sep 02 | Open-market sale · S | −17,557 | $66.28 | −$1.16M | 61,003 |
| Countouriotis Athena | Director | Jun 02 | Grant / award · A | +7,490 | — | — | 21,040 |
| Enyedy Mark J | Director | Jun 02 | Grant / award · A | +7,490 | — | — | 21,040 |
| Anderson Elizabeth M | Director | Jun 02 | Grant / award · A | +7,490 | — | — | 41,940 |
| Bodem Barbara W. | Director | Jun 02 | Grant / award · A | +7,490 | — | — | 21,045 |
| Hombach Robert J. | Director | Jun 02 | Grant / award · A | +7,490 | — | — | 49,360 |
| Dere Willard H | Director | Jun 02 | Grant / award · A | +7,490 | — | — | 46,440 |
| Clark Ian T | Director | Jun 02 | Grant / award · A | +7,490 | — | — | 14,490 |
| Ho Maykin | Director | Jun 02 | Grant / award · A | +7,490 | — | — | 35,500 |
| Walbert Timothy P | Director | Jun 02 | Grant / award · A | +7,490 | — | — | 17,270 |
| Hubbard Cristin | EVP, Chief Commercial Officer | May 20 | Withheld — tax / exercise cost · F | −2,318 | $50.20 | −$116K | 42,472 |
| Friberg Gregory R | EVP, Chief R&D Officer | May 07 | Open-market sale · S | −3,281 | $53.85 | −$177K | 51,818 |
| Davis George Eric | EVP, Chief Legal Officer | Mar 18 | Withheld — tax / exercise cost · F | −1,273 | $56.05 | −$71.4K | 78,560 |
| Hardy Alexander | Chief Executive Officer | Mar 17 | Withheld — tax / exercise cost · F | −4,252 | $56.05 | −$238K | 214,635 |
| Mueller Brian | EVP, Chief Financial Officer | Mar 17 | Withheld — tax / exercise cost · F | −2,117 | $56.05 | −$119K | 123,314 |
| Guyer Charles Greg | EVP, Chief Technical Officer | Mar 17 | Withheld — tax / exercise cost · F | −1,693 | $56.05 | −$94.9K | 84,140 |
| Friberg Gregory R | EVP, Chief R&D Officer | Mar 17 | Withheld — tax / exercise cost · F | −1,629 | $56.05 | −$91.3K | 55,099 |
| Hubbard Cristin | EVP, Chief Commercial Officer | Mar 17 | Withheld — tax / exercise cost · F | −1,245 | $56.05 | −$69.8K | 44,790 |
Loading...
